Sihuan Pharmaceutical Holdings Group Ltd
Company Profile
Business description
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company. Along with its subsidiaries, the company is engaged in the research & development and the manufacture & sale of pharmaceutical products. Its portfolio comprises products for diseases related to the cardio-cerebral vascular (CCV) system, Respiratory, Neurology, and others. The group has three reportable segments: the medical aesthetic products segment, including the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skincare, and others; the innovative medicine and other medicine segment; and the generic medicine segment, which generates key revenue. Geographically, the company generates a majority of its revenue from Mainland China and the rest from the United States.
Contact
1 Harbour Road, Convention Plaza
Room 4905, Office Tower
Wanchai
HKGT: +852 36283911
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
2,843
Stocks News & Analysis
stocks
ASX healthcare share undervalued post earnings
stocks
ASX energy share sees 363% increase in dividend
stocks
Wide moat share remains cheap despite rising costs
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,338.80 | 54.50 | -0.58% |
| CAC 40 | 8,478.57 | 39.37 | 0.47% |
| DAX 40 | 26,324.35 | 58.21 | 0.22% |
| Dow JONES (US) | 53,577.40 | 160.24 | 0.30% |
| FTSE 100 | 10,876.36 | 9.80 | -0.09% |
| HKSE | 25,652.97 | 141.87 | 0.56% |
| NASDAQ | 26,151.30 | 171.11 | 0.66% |
| Nikkei 225 | 66,262.16 | 405.73 | 0.62% |
| NZX 50 Index | 14,013.21 | 20.49 | 0.15% |
| S&P 500 | 7,677.28 | 24.42 | 0.32% |
| S&P/ASX 200 | 9,127.80 | 55.90 | -0.61% |
| SSE Composite Index | 3,912.52 | 23.08 | 0.59% |